

Case Report

Neonatal metabolic crisis: a case report of HMG-CoA lyase deficiency

Amrutha Nandini Ratnapu^{1*}, Venkataramana Reddy², Chapay Soren²,
M. Geethika³, K. Puja Devi²

¹SVS Medical College, Mahabubnagar, Telangana, India

²Department of Pediatrics, SVS Medical College, Mahabubnagar, Telangana, India

³Department of Radiology, SVS Medical College, Mahabubnagar, Telangana, India

Received: 10 February 2025

Accepted: 10 March 2025

*Correspondence:

Dr. Amrutha Nandini Ratnapu,

E-mail: amruthanandiniratnapu@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) lyase deficiency is a rare autosomal recessive metabolic disorder characterized by impaired ketogenesis and leucine catabolism, leading to nonketotic hypoglycemia, hyperammonemia, and metabolic acidosis. We present a case of a three-day-old male neonate who exhibited poor feeding, lethargy, and respiratory distress, progressing to clonic seizures and severe metabolic decompensation. Initial laboratory findings revealed hypoglycemia, hyperlactatemia, hyperammonemia, and metabolic acidosis with absent ketones. A comprehensive metabolic workup, including urinary organic acid analysis and tandem mass spectrometry, confirmed the diagnosis of HMG-CoA lyase deficiency. The neonate was managed with intravenous dextrose, sodium bicarbonate, and L-carnitine supplementation, leading to gradual clinical improvement. This case highlights the importance of early recognition and prompt management of inborn errors of metabolism, particularly in neonates presenting with acute metabolic crises. The report underscores the need for comprehensive newborn screening to facilitate early diagnosis and prevent life-threatening complications.

Keywords: HMG-CoA lyase deficiency, Neonatal metabolic crisis, Nonketotic hypoglycemia, Hyperammonemia, Metabolic acidosis, Neonatal seizures

INTRODUCTION

3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) lyase deficiency is a rare autosomal recessive disorder of ketogenesis and leucine catabolism, first described by Faull in 1976.¹ This disorder results from mutations in the HMGCL gene, leading to the accumulation of toxic intermediates in the leucine degradation pathway and impaired production of ketone bodies. The estimated prevalence of HMG-CoA lyase deficiency is fewer than 1 in 100,000 live births, though this may be an underestimation due to misdiagnosis or underreporting.² A recent systematic review identified 211 reported cases, with an overall mortality rate of 16%.³ The clinical presentation of HMG-CoA lyase deficiency typically occurs in the neonatal period or early infancy, often triggered by fasting, infection, or excessive physical

exertion. Affected individuals present with acute metabolic decompensation, characterized by hypoketotic hypoglycemia, metabolic acidosis, hyperammonemia, and hyperlactatemia. These metabolic disturbances can lead to severe complications, including seizures, lethargy, coma, and even death if not promptly managed. The absence of ketone bodies during hypoglycemia is a hallmark of this condition, as the body is unable to utilize ketones as an alternative energy source.

Despite the severity of the initial presentation, early diagnosis and appropriate management can lead to favorable long-term outcomes. However, the nonspecific nature of the symptoms often leads to delayed diagnosis or misdiagnosis, particularly in settings where metabolic screening is not routinely performed. This case report describes a neonate with HMG-CoA lyase deficiency

who presented with acute metabolic decompensation, highlighting the challenges in diagnosis and the importance of early intervention. The report also emphasizes the role of comprehensive metabolic workup and dietary management in improving outcomes for patients with this rare disorder.

CASE REPORT

A three-day-old male neonate was admitted to the NICU with a day history of poor feeding, decreased activity, and increased work of breathing. The child was a late preterm born at 36 weeks of gestation to a primi mother with 2nd-degree consanguinity via elective cesarean section (LSCS). APGAR score was not recorded. However, the mother denied any delay in crying. Regular antenatal checkups were conducted, with a maternal history of fever lasting 10 days during the third month of pregnancy, for which she received oral antibiotics.

There was no history of urinary symptoms, abnormal vaginal discharge, prolonged rupture of membranes, or foul-smelling amniotic fluid. Supplementations were received as per the guidelines. The child was exclusively breastfed immediately after the delivery. The neonatal anthropometry included a weight of 2.8 kg, a length of 46 cm, and a head circumference of 33 cm. For the first three days of life, he was alert, active, and breastfeeding well. At the end of the third day, the mother noticed a gradual decline in activity, followed by poor feeding, and lethargy associated with an increased respiratory effort.

These observations led to the infant's immediate admission to the NICU for further evaluation and management. On the day of admission, the baby developed clonic seizures with low blood glucose. Family history revealed an unexplained death of a previous sibling at 7 months of age, who presented with respiratory distress.

Clinical examination

Upon examination, the neonate exhibited a weak cry, poor sucking, reduced activity, signs of dehydration, and a flat anterior fontanelle. The Moro reflex was bilaterally symmetrical but incomplete, and no obvious external congenital anomalies were noted. The Silverman-Anderson respiratory severity score was 4, indicating moderate respiratory distress.

A comprehensive set of investigations were performed to assess possible metabolic, infectious, and endocrine causes. Routine laboratory tests, including hemogram, serum electrolytes, arterial blood gas analysis, and chest X-ray, were conducted. Sepsis screening included C-reactive protein, procalcitonin, and cultures of blood, urine, and cerebrospinal fluid (CSF). A metabolic workup was initiated, evaluating serum glucose, ketones, lactate, ammonia, and urine ketones. Additionally, endocrine assessments, including serum insulin, cortisol, and

thyroid function tests, were performed. Given the presence of seizures and hypotonia, the neonate was intubated and administered anti-seizure medication. During the course of illness, he developed coagulopathy, necessitating platelet transfusion and vitamin K administration. Metabolic abnormalities, including hypoglycemia and acidosis, were managed with intravenous 10% dextrose and sodium bicarbonate. Considering the possibility of vitamin-responsive inborn errors of metabolism, the infant was also resuscitated with thiamine and biotin.

Laboratory findings revealed hypoglycemia, elevated lactate (40.2 mg/dl), hyperammonemia (222 µg/dl), metabolic acidosis (pH 7.15) with increased anion gap (16 mEq/l), and absent serum and urine ketones. Coagulation abnormalities included prolonged PT (37.5 seconds; control: 13.5 seconds), elevated INR (5.09), and increased D-dimer (1520 µg/l), as shown in table 1 below. Mild transaminitis was noted (AST: 52 IU/l, ALT: 39 IU/l, reference range: 10–37 IU/l). Considering possible intrauterine infection, pneumonia, meningitis, or sepsis, a comprehensive infectious disease workup, including blood, urine, and CSF cultures, were performed and found to be negative. Neuroimaging findings showed no evidence of meningitis.




Figure 1: T2 axial, on day 11, showing bilateral occipital lobe and splenium of corpus callosum hyperintensity.

Differential diagnosis

Based on the preliminary history and laboratory findings, a metabolic disorder was strongly suspected, given the presence of high anion gap metabolic acidosis, hyperammonemia and hyperlactatemia, and hypoglycemia with absent ketone bodies. These findings were indicative of acylcarnitine-related conditions, such

severity of the initial presentation, most patients achieve a favourable long-term outcome with normal cognitive development.^{2,4}

During hypoglycemia, the body compensates by producing ketone bodies as an alternative energy source. However, in HMGCL deficiency, this compensatory mechanism is impaired due to defective ketogenesis, leading to a nonketotic hypoglycemic state. Since HMG-CoA lyase also plays a crucial role in leucine catabolism, its deficiency results in accumulation of leucine and its toxic metabolites, preventing their conversion into essential downstream products, such as acetoacetate and acetyl-CoA, which are critical for energy production.

This leads to a build-up of toxic intermediates, including 3-methylglutaconyl-CoA (3-MGC), 3-methylglutaconate (3-MGL), and 3-hydroxyisovalerate (3-HIVA). The combination of ketone body deficiency and toxic metabolite accumulation severely disrupts metabolic homeostasis, leading to secondary metabolic dysfunction, and in severe cases, acute encephalopathy. Due to its impact on fatty acid metabolism and organic acid accumulation, HMGCL deficiency is classified as both a fatty acid oxidation disorder and an organic aciduria.^{3,5}

Despite this metabolic imbalance, amino acid levels were found to be normal in our case. Symptoms typically emerge following fasting, infection, increased dietary protein intake, or the stress of birth. Affected individuals frequently present with acute metabolic decompensation, characterized by hypoketotic hypoglycemia, metabolic acidosis, vomiting, dehydration, hypotonia, and lethargy. The combination of nonketotic hypoglycemia, hyperammonemia, and hyperlactatemia strongly suggests an inborn error of metabolism.

However, due to its rare incidence and nonspecific clinical presentation, the diagnosis of HMG-CoA lyase deficiency is often delayed or misdiagnosed. In our case, the neonate was initially treated for sepsis, given risk factors such as preterm LSCS delivery, low birth weight, respiratory distress, and hypotonia, before further metabolic investigations identified the underlying disorder.^{6,2}

Although there are no standardized guidelines for dietary management, evidence from previous case studies suggests that a leucine-, protein-, and fat-restricted diet can improve prognosis.^{3,4} The mother was counseled to follow dietary modifications, particularly during illness, when the body enters a catabolic state, leading to increased protein breakdown and additional strain on the liver. Frequent feeding was recommended to prevent fasting-induced metabolic crises, along with nocturnal cornstarch supplementation to provide a sustained energy source. Additionally, elevated C5OH (3-

hydroxyisovalerylcarnitine) indicated secondary carnitine deficiency, which occurs due to organic acid conjugation with free carnitine, leading to carnitine depletion and impaired fatty acid oxidation. To counteract this, the neonate was supplemented with L-carnitine to restore metabolic balance.⁴

CONCLUSION

This case underscores the necessity of considering inborn errors of metabolism, such as HMG-CoA lyase deficiency, even when amino acid levels appear normal. It highlights the crucial role of comprehensive newborn screening in the early identification and management of metabolic disorders to prevent life-threatening complications.

Funding: No funding sources

Conflict of interest: None declared

Ethical approval: Not required

REFERENCES

1. Faull K, Bolton P, Halpern B, Hammond J, Danks DM, Hähnel R, et al. Letter: Patient with defect in leucine metabolism. *Engl J Med.* 1976;294:1013.
2. Santarelli F, Cassanello M, Enea A, Poma F, D'Onofrio V, Guala G, et al. A neonatal case of 3-hydroxy-3-methylglutaric-coenzyme A lyase deficiency. *Italian J Pediatrics/Italian J Pediat.* 2013;39(1):33.
3. Thompson S, Hertzog A, Selvanathan A, Batten K, Lewis K, Nisbet J, et al. Treatment of HMG-CoA Lyase Deficiency—Longitudinal Data on Clinical and Nutritional Management of 10 Australian Cases. *Nutrients.* 2023;15(3):531.
4. Grünert SC, Sass JO. 3-hydroxy-3-methylglutaryl-coenzyme A lyase deficiency: one disease - many faces. *Orpha J of Rare Diseases.* 2020;15(1):1319-7.
5. Arnedo M, Latorre-Pellicer A, Lucia-Campos C, Gil-Salvador M, Antónanzas-Peréz R, Gómez-Puertas P, et al. More Than One HMG-CoA Lyase: The Classical Mitochondrial Enzyme Plus the Peroxisomal and the Cytosolic Ones. *International J Mol Sci.* 2019;20(24):6124.
6. Alfadhel M, Abadel B, Almaghthawi H, Umair M, Rahbeeni Z, Faqeh E, et al. HMG-CoA Lyase Deficiency: A Retrospective Study of 62 Saudi Patients. *Frontiers in Genetic.* 2022;13:613.

Cite this article as: Ratnapu AN, Reddy V, Soren C, Geethika M, Devi KP. Neonatal metabolic crisis: a case report of HMG-CoA lyase deficiency. *Int J Contemp Pediatr* 2025;12:696-9.